Literature DB >> 12679913

Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis.

Chang-Xin Geng1, Zhao-Chong Zeng, Ji-Yao Wang.   

Abstract

AIM: To investigate the in vitro anti-hepatocellular carcinoma (HCC) activity of docetaxel against SMMC-7721 HCC cells and its possible mechanism.
METHODS: The HCC cells were given different concentrations of docetaxel and their growth was measured by colony forming assay. Cell cycle and apoptosis were analyzed by flow cytometry and fluorescence microscopy (acridine orange/ethidium bromide double staining, AO/EB), as well as electronic microscopy. The SMMC-7721 HCC cell reactive oxygen species (ROS) and glutathione (GSH) were measured after given docetaxel.
RESULTS: Docetaxel inhibited the hepatocellular carcinoma cells growth in a concentration dependent manner with IC(50) 5 x 10(-10)M. Marked cell apoptosis and G2/M phase arrest were observed after treatment with docetaxel >=10(-8)M. Docetaxel promoted SMMC-7721 HCC cells ROS generation and GSH deletion.
CONCLUSION: Docetaxel suppressed the growth of SMMC-7721 HCC cells in vitro by causing apoptosis and G2/M phase arrest of the human hepatoma cells, and ROS and GSH may play a key role in the inhibition of growth and induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12679913      PMCID: PMC4611431          DOI: 10.3748/wjg.v9.i4.696

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  Prospect of gastroenterology and hepatology in the next century.

Authors:  Rudi Schmid
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

Review 2.  Review: The role of glutathione in the regulation of apoptosis.

Authors:  A G Hall
Journal:  Eur J Clin Invest       Date:  1999-03       Impact factor: 4.686

3.  Induction of mild intracellular redox imbalance inhibits proliferation of CaCo-2 cells.

Authors:  T Noda; R Iwakiri; K Fujimoto; T Y Aw
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

4.  Activation of the protein kinase p38 in the spindle assembly checkpoint and mitotic arrest.

Authors:  K Takenaka; T Moriguchi; E Nishida
Journal:  Science       Date:  1998-04-24       Impact factor: 47.728

5.  Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP)

Authors:  U Vanhoefer; S Cao; A Harstrick; S Seeber; Y M Rustum
Journal:  Ann Oncol       Date:  1997-12       Impact factor: 32.976

6.  Synergistic anticancer activity of 1,25-dihydroxyvitamin D(3) and immune cytokines: the involvement of reactive oxygen species.

Authors:  R Koren; D Rocker; O Kotestiano; U A Liberman; A Ravid
Journal:  J Steroid Biochem Mol Biol       Date:  2000-06       Impact factor: 4.292

7.  Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines.

Authors:  Mariko Kito; Yukihiro Akao; Nobuko Ohishi; Kunio Yagi; Yoshinori Nozawa
Journal:  Biochem Biophys Res Commun       Date:  2002-03-08       Impact factor: 3.575

8.  Relationships between the structure of taxol analogues and their antimitotic activity.

Authors:  F Guéritte-Voegelein; D Guénard; F Lavelle; M T Le Goff; L Mangatal; P Potier
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

Review 9.  Preclinical evaluation of docetaxel (Taxotere).

Authors:  F Lavelle; M C Bissery; C Combeau; J F Riou; P Vrignaud; S André
Journal:  Semin Oncol       Date:  1995-04       Impact factor: 4.929

10.  A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.

Authors:  S Cascinu; F Graziano; S Barni; R Labianca; G Comella; R Casaretti; L Frontini; V Catalano; A M Baldelli; G Catalano
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

View more
  7 in total

1.  Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma.

Authors:  Weihua Qiu; Bingsen Zhou; Hongzhi Zou; Xiyong Liu; Peiguo G Chu; Richard Lopez; Jennifer Shih; Christopher Chung; Yun Yen
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

2.  Novel hydrophilic docetaxel (CQMU-0519) analogue inhibits proliferation and induces apoptosis in human A549 lung, SKVO3 ovarian and MCF7 breast carcinoma cell lines.

Authors:  N J S Fauzee; Y-L Wang; Z Dong; Q-G Li; T Wang; M T Mandarry; L Xu; J Pan
Journal:  Cell Prolif       Date:  2012-06-05       Impact factor: 6.831

3.  Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo.

Authors:  Cheng Jin; Haimin Li; Yong He; Min He; Ling Bai; Yunxin Cao; Wenjie Song; Kefeng Dou
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

4.  Growth arrest and apoptosis of human hepatocellular carcinoma cells induced by hexamethylene bisacetamide.

Authors:  Gao-Liang Ouyang; Qiu-Feng Cai; Min Liu; Rui-Chuan Chen; Zhi Huang; Rui-Sheng Jiang; Fu Chen; Shui-Gen Hong; Shi-Deng Bao
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

5.  Protein profile of human hepatocarcinoma cell line SMMC-7721: identification and functional analysis.

Authors:  Yi Feng; Zhong-Min Tian; Ming-Xi Wan; Zhao-Bin Zheng
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

Review 6.  Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.

Authors:  Herbert H Loong; Winnie Yeo
Journal:  Onco Targets Ther       Date:  2014-04-16       Impact factor: 4.147

7.  Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma.

Authors:  Hongjun Xie; Muqi Shi; Yifei Liu; Changhong Cheng; Lining Song; Zihan Ding; Huanzhi Jin; Xiaohong Cui; Yan Wang; Dengfu Yao; Peng Wang; Min Yao; Haijian Zhang
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.